Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 9/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 9/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Naphthol SCHEMBL28212404 | 0.85 | CYP1A2 (0.59) | PLAUHSD17B1HSD17B2CYP1A2CTDSP1 | |
| SCHEMBL15345538 | 0.82 | PLAU (0.58) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL3359160 | 0.82 | CYP1A2 (0.53) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| 1-Naphthol SCHEMBL27503865 | 0.82 | CYP1A2 (0.71) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL3045619 | 0.80 | MAPK1 (0.45) | CYP1A2 | |
| SCHEMBL30504155 | 0.80 | MAPK1 (0.45) | CYP1A2 | |
| SCHEMBL8922542 | 0.79 | IDH1 (0.56) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL5541800 | 0.79 | CNR1 (0.52) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL30293100 | 0.79 | GRIN2D (0.42) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL7221961 | 0.78 | SLC9A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| CN-101177385-B | Aryl sulfonic acid amides and analogues as well as its purpose in curing neural degeneration disease | BAYER AG | 2011-06-15 | — | — | CN | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| CN-100453529-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2009-01-21 | — | — | CN | disclosed |
| CN-101177385-A | Aryl sulfonic acid amides and analogues as well as its purpose in curing neural degeneration disease | BAYER AG (DE) | 2008-05-14 | — | — | CN | disclosed |
| CN-100371318-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2008-02-27 | — | — | CN | disclosed |
| CN-1754873-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2006-04-05 | — | — | CN | disclosed |
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| EP-0966436-B1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| CN-1253545-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2000-05-17 | — | — | CN | disclosed |
| EP-0966436-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Bayer Aktiengesellschaft (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998037061-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | PLAU 2978/4885HSD17B1 2015/4885HSD17B2 2573/4885 |
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | PLAU 1508/4885HSD17B1 3314/4885HSD17B2 2804/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PLAU 3658/4885HSD17B1 4042/4885HSD17B2 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.